EPRX – eupraxia pharmaceuticals inc. (US:NASDAQ)
Stock Stats
News
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its price target raised by analysts at Cantor Fitzgerald from $11.00 to $19.00. They now have an "overweight" rating on the stock.
Eupraxia Pharmaceuticals (NASDAQ:EPRX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy [Yahoo! Finance]
Eupraxia Pharmaceuticals Up 1.8% As Reports "Positive" Findings From Resolve Trial [Yahoo! Finance]
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy 
Form 6-K EUPRAXIA PHARMACEUTICALS For: Jan 08
Form SCHEDULE 13G/A EUPRAXIA PHARMACEUTICALS Filed by: DISBROW ROBERT
Form SCHEDULE 13G EUPRAXIA PHARMACEUTICALS Filed by: Beutel, Goodman & Co Ltd.
Form SCHEDULE 13G EUPRAXIA PHARMACEUTICALS Filed by: MANCHESTER MANAGEMENT CO LLC
Form 6-K EUPRAXIA PHARMACEUTICALS For: Nov 04
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.